H. Jack West

lung cancer nsclc cancer egfr mutation afatinib oncology erlotinib acquired resistance avastin crizotinib tarceva egfr alk rearrangement t790m non-small cell lung cancer ceritinib gefitinib bevacizumab xalkori gilotrif ramucirumab targeted therapy azd9291 sclc iressa local therapy maintenance therapy chemotherapy tivantinib c-met genomic testing immune checkpoint inhibitor cancer care social media bibw-2992 ned molecular testing metastatic cancer arq-197 molecular oncology systemic therapy micrometastases advanced cancer no evidence of disease resistance adaptation evolution side effects patient groups engaged patients e-patients online patient communities egfr inhibitor medicine 2.0 cetuximab tki erbitux metmab ldk378 nonprofit alk alectinib eml4-alk del 19 l858r exon 21 co-1686 exon 19 ngs nintedinib ldct low dose chest ct screening precision medicine personalized medicine cancer genetics next generation sequencing genomics rova-t low molecular weight heparin antibody-drug conjugate small cell lung cancer paclitaxel nedroparin immunotherapy taxol avelumab lmwh adjuvant therapy dll3 lung cancer risk somatic mutation ct screening germline mutation grace disease progression response assessment cancer progression advanced nsclc stage iv lung cancer locally advanced stage 3 stage iii nsclc locally advanced nsclc radiation surgery chemo/radiation multidisciplinary alimta zykadia pemetrexed prophylactic cranial irradiation co1686 thoracic radiation therapy necitumumab bevacizumab/erlotinib taxotere